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itabine 14%, vinorelbine 11% or geﬁtinib 9%). Approximately
one-quarter of patients were treated in third line and approxi-
mately 10% received fourth line treatment. The vast majority of
third and fourth line treatments involved single agents. Toxici-
ties associated with drug therapy were consistent with those that
have been previously reported elsewhere. CONCLUSION: In the
ﬁrst line of therapy, patients received care largely reﬂecting the
existing NSCLC evidence base from controlled trial data avail-
able during the 2001–2003 period. Treatment patterns and out-
comes of patients in community-based practices represent a
potential rich source of data to complement controlled trial data.
To improve the availability of real-world practice data, further
work is necessary to overcome limitations of claims-based oncol-
ogy data, to enhance the development of analyzable electronic
health records, and to establish treatment registries.
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OBJECTIVES: Two ESTs received FDA-approval for ﬁxed initial
dosing in cancer patients with chemotherapy-induced anemia:
40,000 units for epoetin alfa (EPO) and 500 mcg for darbepo-
etin alfa (DARB). Understanding cost considerations, data was
analyzed from the Dosing and Outcomes Study of Erythro-
poiesis-Stimulating Therapies (D.O.S.E.) Registry, an ongoing,
prospective registry collecting data on real-world practice pat-
terns. METHODS: Data from 18 U.S. hospital and community-
based outpatient practices were assessed from January
2006–December 2006. Chemotherapy-treated adult patients ini-
tiated on either EPO 40,000 Units or DARB 500 mcg were eval-
uated. Outcomes assessed included: mean administered dose,
mean treatment duration, dosing patterns, and mean cumulative
administered dose. EST cost was based on dose and 9/2006
wholesale acquisition cost (EPO $12.17/1000 Units; DARB
$4.446/mcg) with sensitivity analysis based on 4Q06 ASP + 6%.
RESULTS: A total of patients (145 EPO, 23 DARB) were eligi-
ble for analysis. Patient groups were similar with regard to base-
line age, gender, tumor type, and Karnofsky score. The
predominant dosing pattern was QW for EPO and Q3W for
DARB. The mean administered dose was EPO 42,879 Units and
497 mcg in DARB group, corresponding to an EST cost of $522
and $2210 per injection. Treatment duration and number of
ofﬁce visits was similar between groups. Mean cumulative
administered dose was 305,241 Units for EPO and 1665 mcg for
DARB. The corresponding EST costs were $3715 for EPO and
$7404 for DARB (p < 0.0001) with similar ﬁndings based on
sensitivity analysis. CONCLUSION: Practice pattern data from
this observational study of cancer patients initiated at FDA-
approved ﬁxed dosing reported signiﬁcantly lower costs in the
EPO group compared to the DARB group. Mean cumulative
drug cost was $3689 less (50% less) in the EPO group compared
to the DARB group. Findings provide further understanding of
anemia management costs for health care professionals, hospital
systems, and patients.
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OBJECTIVES: The Patient Assessment, Care & Education
(PACE) SystemTM was designed to address the persistent
problem of under-identiﬁcation and treatment of chemotherapy-
related symptoms. The PACE SystemTM uses a pen-based
e/Tablet that operates off a wireless network. Cancer Support
NetworkTM on the e/Tablet provides educational materials to
patients in text, video, audio, and graphic format. The PACE 
SystemTM also administers the Patient Care MonitorTM, a psy-
chometrically validated, patient-reported symptom severity
screening scale that generates a real-time, point-of-care report 
for the provider. The aim of the study was determined provider
and patient opinions of the PACE SystemTM and to determine
whether symptom assessment rates increased after the PACE
System was implemented METHODS: Ninety-two providers
(i.e., physicians, nurse practitioners, physician assistants) at 16
community oncology clinics were surveyed about their experi-
ences with the PACE SystemTM In addition, 100 patients at two
community oncology clinics were surveyed about their percep-
tions of the PACE System™. At two oncology clinics 100 patient
charts were abstracted in the year prior to implementation of the
PACE system and in the year after the implementation the PACE
system to determine symptom assessment rates. RESULTS: The
majority of patients reported that they were generally satisﬁed
with the PCM (55%). Slightly more than half indicated that it
helped them to remember symptoms, although only 44% said it
encourage them to discuss their symptoms. 91% of respondents
said the e/tablet was easy to use. The majority of providers
thought that the PCM increased the frequency with which symp-
toms were identiﬁed and treated. The results from the chart
review show statistically signiﬁcant increases in the assessment
rates for depression, pain, and fatigue after the PACE system was
implemented. CONCLUSION: The PACE system appears to be
a promising approach to addressing the widespread problem 
of under-identiﬁcation and under-treatment of symptoms in
patients undergoing cancer treatment.
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OBJECTIVES: Two national evidence-based guidelines recom-
mend initiation of erythropoiesis stimulating proteins (ESPs) in
chemotherapy-induced anemia (CIA) at hemoglobin (Hb) levels
of °Ü 10 g/dL per ASH/ASCO guideline (2002) and <11 g/dL per
NCCN guideline (1998), and maintenance of Hb near but not
over 12 g/dL. The extent to which these guidelines are followed
in actual practice is unknown. This retrospective study examined
the patterns of ESP use in cancer patients with CIA. METHODS:
The Varian Medical Oncology database of electronic medical
records (EMRs) from 17 outpatient oncology practices in the US
was utilized. Adults with a malignant tumor diagnosis between
January 1, 2004 and July 27, 2006 who received at least one
cycle of chemotherapy were studied. The proportion of patients
